CASI Pharmaceuticals

CASIF · NASDAQ

$0.1001+$0.00 (+0.00%)TodayMarket closed · Oct 20, 11:54 AM ET

Prev close $0.1001

About CASIF

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.

Employees: 233
Headquarters: Beijing, Beijing
Listed: Aug 23, 2021
Sector: Health Care
Industry: Biotechnology
Website: casipharmaceuticals.com

Leadership

CASI Pharmaceuticals executives
Name	Title	Since	Age
Wei-Wu He	—	2012	60
Daniel Lang	—	—	58
Chunhua Wang	—	—	53
Huang Hai	—	—	56
Alexander Zukiwski	—	—	66
Wei Zhang	—	—	65
Kun Qian	—	—	43
Wei Gao	—	—	43
Thomas Folinsbee	—	—	58
Zhenbo Su	—	—	49
Y. Alexander Wu	—	—	62
Xuebo Zeng	—	—	40
Rui Zhang	—	2023	—

Similar companies

Companies in the same industry as CASI Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.